Inhibiting the hormone somatostatin may be a new treatment strategy to prevent dangerous blood glucose drops in type 1 diabetes. This has been shown by a study conducted at, among others ...

The company’s key product is P2045, a proprietary somatostatin (SST) peptide optimized for radioisotope binding. Two lead compounds are in clinical trials for lung cancer—therapeutic candidate ...

Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients with gastroenteropancreatic neuroendocrine tumors, a phase 3 trial found.

Medical treatment of the disease is usually with somatostatin analogs. An open, prospective, single-center study by Maiza et al. examined the long term (≤18 years) antihormonal and antitumor ...

Matching adjusted indirect comparison (MAIC) of 177Lu-DOTATATE vs. sunitinib as first-line (1L) treatment for advanced grade 2 (G2) pancreatic neuroendocrine tumors (pNETs). This is an ASCO Meeting ...

Lanreotide, the active component of Somatuline Depot is an octapeptide analog of natural somatostatin. The mechanism of action of lanreotide is believed to be similar to that of natural somatostatin.

More information: Laura Mòdol et al, Somatostatin interneurons control the timing of developmental desynchronization in cortical networks, Neuron (2024). DOI: 10.1016/j.neuron.2024.03.014 ...